January 2025

On January 27, Yuanpin Biotech's independently developed Class 1 biological new drug, "Human Amniotic Mesenchymal Stem Cell Injection", had its IND application for an additional indication officially accepted by the Center for Drug Evaluation (CDE), proposing its use for the treatment of chronic obstructive pulmonary disease (COPD).